Brief: Chugai Pharmaceutical Co Conclusion Of Exclusive Licensing And Capital Tie-Up Agreements Concerning "Telomelysin (Obp-301)," Oncolytic Viral Immunotherapy
08/04/2019 08:30
April 8 (Reuters) - Chugai Pharmaceutical Co Ltd 4519.T :
* CONCLUSION OF EXCLUSIVE LICENSING AND CAPITAL TIE-UP
AGREEMENTS
CONCERNING "TELOMELYSIN (OBP-301)," ONCOLYTIC VIRAL
IMMUNOTHERAPY
Source text for Eikon: ID:nTSPH62102
Further company coverage: 4519.T
(Reporting By Chris Gallagher)
((chris.gallagher@thomsonreuters.com;))
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)